Improving Outcomes in Lethal Prostate Cancer Through Guideline-Concordant Use of Bone-Modifying Agents
Abstract
We used SEER-Medicare data to identify BMA underuse and overuse among prostate cancer patients, and then evaluated key patient, provider, and practice characteristics for association with underuse (tilde 68 percent receive BMAs appropriately) and overuse (tilde 1/3 non-candidate patients received BMAs inappropriately) [Aim 1]. We conducted in-depth interviews with prostate cancer clinicians to further understand barriers and facilitators to appropriate BMA use [Aim 2A]. We applied findings from Aim 1 and Aim 2A to refine a multi-pronged interventional strategy intended to reduce BMA underuse and overuse. Starting with a set of evidence-based healthcare interventions, we used our findings to incorporate additional components tailored to correcting the barriers we identified [Aim 2B]. We have collected baseline data on guideline-concordant BMA usage within the MSK Alliance, a hybrid academic community network of oncology providers in the Eastern US, and we will pilot our intervention strategy within the MSK Alliance [Aim 3].
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1223427
Entities
People
- Aaron Mitchell
- Akriti Mishra
- Nirjhar Chakraborty
- Sonia Persaud
- Susan Chimonas
Organizations
- Memorial Sloan Kettering Cancer Center